Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

20221,006 citationsJournal Articlebronze Open Access

Authors

Javier Cortés · Cancer Research Institute

Hope S. Rugo · Cancer Research Institute

David W. Cescon · Cancer Research Institute

Seock‐Ah Im · Cancer Research Institute

Mastura Md Yusof · Cancer Research Institute

Carlos Gallardo · Cancer Research Institute

Oleg Lipatov ·

Abstract

Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone. (Funded by Merck Sharp and Dohme; KEYNOTE-355 ClinicalTrials.gov number, NCT02819518.).

Topics & Keywords

Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 3, pp. 217-226

DOI: 10.1056/nejmoa2202809

Field-Weighted Citation Impact: 86.83